Plan A
Pre-clinical- Indications
- Male contraception
Company intelligence / Profile preview
Plan A™, the company's lead program, has shown promising preclinical results demonstrating effective and reversible male contraception using a non-hormonal hydrogel injected into the vas deferens. Restoration of sperm flow was rapid after dissolving the gel in animal studies. The company initiated first-in-human clinical trials in early 2024 and plans larger pivotal studies toward FDA submission and potential market launch by ~2027. No peer-reviewed human efficacy data published as of June 2025.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Next Life Sciences.